Comparison between PD‐1/PD‐L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model. Issue 11 (25th September 2018) - Wu, Yingcheng; Lin, Lifeng; Shen, Yanting; Wu, Huiqun